» Articles » PMID: 27534773

Recent Viral Infection in US Blood Donors and Health-related Quality of Life (HRQOL)

Overview
Journal Qual Life Res
Date 2016 Aug 19
PMID 27534773
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Blood donors are considered to be one of the healthiest populations, but relatively little is known about their perceived quality of life. The objective was to examine HRQOL in donors infected with HIV, HBV, HCV or HTLV and a comparison group.

Methods: Donors with confirmed viral infection (cases) and donors who tested false-positive (controls) participated in a multicenter study of US blood donors (2010-2013), funded by the National Heart, Lung and Blood Institute (NHLBI). HRQOL was measured by the EuroQol Five Dimension (EQ-5D) instrument and EQ-5D visual analogue scale (VAS). The lower 25th ‰ of EQ-5D index or VAS score of controls was defined as a "lower HRQOL."

Results: A total of 1574 controls completed the HRQOL assessment with a mean EQ-5D index of 0.94 (SD = 0.10) and EQ-VAS of 87.6 (SD = 10.6). Mean EQ-5D index for 192 HIV-, 315 HCV- and 195 HTLV-positive donors were significantly lower than the controls (0.86, 0.83 and 0.87; SD = 0.18, 0.20 and 0.16, respectively, p < 0.001). HBV-positive donors (n = 290) had a similar mean EQ-5D index (0.93, SD = 0.14, p = 0.05) to controls. Anxiety/depression was reported by 34 % of cases, compared with 13 % of controls. In multivariable modeling, the odds of lower HRQOL in HIV, HBV, HCV and HTLV cases were 2.1, 1.6, 2.6 and 2.3 times that of controls, respectively (p < 0.05).

Conclusions: HRQOL reported by blood donors with recent viral infections was relatively high but lower than controls. On average, HRQOL among HCV-positive donors was the lowest and HBV-positive donors reported scores similar to donors without infection.

Citing Articles

Health Utilities in People with Hepatitis C Virus Infection: A Study Using Real-World Population-Level Data.

Saeed Y, Mitsakakis N, Feld J, Krahn M, Kwong J, Wong W Med Decis Making. 2025; :272989X251319342.

PMID: 39985398 PMC: 11894892. DOI: 10.1177/0272989X251319342.


Influence of polysubstance use on the health-related quality of life among people who inject drugs undergoing opioid agonist treatment following treatment for hepatitis c virus.

Gormley M, Zhang W, Self S, Ewing J, Heo M, Roth P J Subst Use. 2024; 29(5):836-842.

PMID: 39502837 PMC: 11534293. DOI: 10.1080/14659891.2023.2254391.


Recent Developments in Semiconductor-Based Photocatalytic Degradation of Antiviral Drug Pollutants.

Zhang Z, He D, Zhao S, Qu J Toxics. 2023; 11(8).

PMID: 37624197 PMC: 10458903. DOI: 10.3390/toxics11080692.


The antiviral potential of Phyllanthus species: a systematic review.

Upadhyay R, Tiwari K Arch Virol. 2023; 168(7):177.

PMID: 37310509 DOI: 10.1007/s00705-023-05802-w.


Current standard values of health utility scores for evaluating cost-effectiveness in liver disease: A meta-analysis.

Ishinuki T, Ota S, Harada K, Kawamoto M, Meguro M, Kutomi G World J Gastroenterol. 2022; 28(31):4442-4455.

PMID: 36159009 PMC: 9453766. DOI: 10.3748/wjg.v28.i31.4442.


References
1.
Rabin R, de Charro F . EQ-5D: a measure of health status from the EuroQol Group. Ann Med. 2001; 33(5):337-43. DOI: 10.3109/07853890109002087. View

2.
Shaw J, Johnson J, Coons S . US valuation of the EQ-5D health states: development and testing of the D1 valuation model. Med Care. 2005; 43(3):203-20. DOI: 10.1097/00005650-200503000-00003. View

3.
Kanwal F, Gralnek I, Martin P, Dulai G, Farid M, Spiegel B . Treatment alternatives for chronic hepatitis B virus infection: a cost-effectiveness analysis. Ann Intern Med. 2005; 142(10):821-31. DOI: 10.7326/0003-4819-142-10-200505170-00007. View

4.
Custer B, Kamel H, Kiely N, Murphy E, Busch M . Associations between West Nile virus infection and symptoms reported by blood donors identified through nucleic acid test screening. Transfusion. 2009; 49(2):278-88. DOI: 10.1111/j.1537-2995.2008.01952.x. View

5.
Ullum H, Rostgaard K, Kamper-Jorgensen M, Reilly M, Melbye M, Nyren O . Blood donation and blood donor mortality after adjustment for a healthy donor effect. Transfusion. 2015; 55(10):2479-85. DOI: 10.1111/trf.13205. View